본문 바로가기 주메뉴 바로가기
22대 대한민국 국회 국회정보길라잡이 국회의원검색
회원가입 로그인
HOME

정보검색

소장정보 검색

국회도서관 홈으로 정보검색 소장정보 검색

결과 내 검색

동의어 포함

고급검색

인명/단체명

저자정보 상세정보
인명/단체명을 입력하세요.

키워드

  • 대표어

  • 외국어

-

초록보기

Purpose Tyrosine kinase inhibitors (TKIs) have improved the prognosis of chronic myeloid leukaemia (CML), allowing patients with favourable disease profiles and molecular responses to attempt treatment-free remission (TFR). We aim to establish the relapse-free survival (RFS) outcomes and identify prognostic factors for successful remission maintenance among those who attempt TFR.

Methods Adult CML patients who had undergone TFR from January 1, 2016, to June 30, 2024, were included. Upon TKI discontinuation, real-time quantitative polymerase chain reaction (RQ-PCR) was monitored monthly for the first 12 months, then every 3 months, with TKI reinitiated upon a transcript level above 0.1% (IS). Data analysis was performed using SPSS version 29.0 (SPSS Inc., Chicago, IL, USA).

Results Fifty-seven patients (27 males and 30 females) with a median age of 46 years (range 16 – 70) were analysed.

The majority had a low EUTOS long-term survival (ELTS) score (61.4%, n = 35) and received imatinib (87.7%, n = 50).

The median treatment duration was 8.8 years (range 4.2 – 18.8), and the median duration for sustained deep molecular remission (DMR) was 4.6 years (range 2.1 – 11.1). RFS was 70.2% at 6 months, 62.5% at 12 months and 56.8% at 2 years after a median follow-up of 34 months (range 9 – 101). The MR5 level was identified as an independent factor associated with sustained remission. All relapsed patients achieved DMR upon treatment reinitiation.

Conclusion Treatment discontinuation can be safely performed, with many achieving long-term treatment-free remission. A deeper molecular response (MR5) is associated with an improved likelihood of remission maintenance.

권호기사

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 목차
Molecular spectrum and carrier frequency of deletional hereditary persistence of fetal hemoglobin and delta-beta thalassemia in Malaysia Faidatul Syazlin Abdul Hamid, Sabariah Md Noor, Mei I Lai, Samsol Kamal Mohd Bahari, Ezalia Esa, Ermi Neiza Mohd Sahid, Norafiza Mohd Yasin, Yuslina Mat Yusoff p. 1-8
Novel agents and evolving strategies for anemia management in lower-risk myelodysplastic syndromes Junshik Hong p. 1-7
Treatment of transplant-ineligible multiple myeloma Jongheon Jung p. 1-7
Tandem autologous stem cell transplant in multiple myeloma patients with minimal residual disease : an explorative study Sieun Oh, Sung-Soo Park, Jung Yeon Lee, Jae-Ho Yoon, Sung-Eun Lee, Hee-Je Kim, Seung-Hwan Shin, Young-Woo Jeon, Seung-Ah Yahng, Jin Jung, Ari Ahn, Myungshin Kim, Chang-Ki Min p. 1-10
Aggressive natural killer cell leukemia therapy in the L-asparaginase era : why are we failing? Sang Eun Yoon, Junhun Cho, Hyun-Young Kim, Seok Jin Kim, Won Seog Kim p. 1-13
Unveiling the role of microRNAs, the PI3K/AKT pathway, and their associations in various types of leukemia : a comprehensive review Amir Modarresi Chahardehi, Esfandiar Mali, Arya Afrooghe, Amirmasoud Asadi, Amirreza Khalaji, Hamed Soleimani Samarkhazan, Hananeh Esmaeil Beygi, Amirhossein Mohagheghi, Maryam Khanbabaei, Heliya Haghani, Reza Arefnezhad, Fatemeh Rezaei-Tazangi p. 1-13
Early CD4 + T cell immune reconstitution as a biomarker for Epstein-Barr virus control following allogeneic transplantation Kexin Lin, Wenwen Yang, Jiaxiu Yin, Jing Luo, Hao Zhou, Lanxiang Liu, Li Yang, Jie Luo, Lin Liu, Junli Mou p. 1-10
Beyond anemia : unraveling neutrophil defects and infection susceptibility in β-Thalassemia Chingiz Asadov, Gunay Aliyeva p. 1-10
(Correspondence) Durable responses and favorable cost-effectiveness of rituximab‑based chemoimmunotherapy for primary cold agglutinin disease Kenichi Ito, Tomoko Kitagawa, Saya Motohashi, Kazuhiko Hirano, Naohiro Sekiguchi p. 1-6
(Correspondence) Current immunotherapeutic approaches for relapsed/refractory follicular lymphoma : bispecific antibodies and CAR T-Cell therapies So Yeon Park, Gi-June Min p. 1-6
(A) comparative study of hematologic response to ropeginterferon alfa-2b in hydroxyurea-resistant or intolerant polycythemia vera : a real-world data-based analysis Sung-Eun Lee, Seug Yun Yoon, Sung-Yong Kim, Soo-Mee Bang, Insoo Lee, Jihyuk Lee, Junshik Hong p. 1-7
Plasma interleukin‑12 levels as a potential biomarker of fatigue and quality of life in patients with primary immune thrombocytopenia Sarthak Wadhera, Arihant Jain, Aarushi Sahni, Rudra Narayan Swain, Charanpreet Singh, Aditya Jandial, Ritu Aggarwal, Rekha Hans, Gaurav Prakash, Alka Khadwal, Sandeep Grover, Reena Das, Pankaj Malhotra p. 1-8
Brentuximab vedotin combined with cisplatin, cytarabine, and dexamethasone treatment in transplant‑eligible Korean patients with relapsed or refractory Hodgkin’s lymphoma Jun Ho Yi, Young Hoon Park, Myungwon Lee, Kwai Han Yoo, Junshik Hong, HyeonSeok Eom p. 1-6
Insights into treatment‑free remission (TFR) outcomes in chronic myeloid leukaemia (CML) : a tertiary centre experience in Malaysia Christopher Chin Keong Liam, Yang Liang Boo, Li Min Lim, Siew Lian Chong, Azizan Sharif, Yih Seong Wong, Veena Selvaratnam, Sen Mui Tan, Soo Min Lim p. 1-7
Invasive fungal infections in hematologic diseases : evidence, challenges, and clinical practice SungYeon Cho, Chae Eun Lee, Dukhee Nho, DongGun Lee p. 1-7
(Correspondence) Measurable residual disease monitoring after hematopoietic stem cell transplantation Saeam Shin p. 1-3
(Correspondence) Translational investigation of tolinapant (ASTX660) in acute myeloid leukemia by integrating clinical, bioinformatic and pharmacological approaches Keli Lima, Frederico Lisboa Nogueira, Catarina Sofia Mateus Reis‑Silva, Rita de Cássia Cavaglieri, Leticia Veras Costa‑Lotufo, João Agostinho Machado‑Neto, Eduardo Magalhães Rego p. 1-5

추천서가 (다양한 추천 자료를 만나보세요)

권호기사보기

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 기사목차

권호

기사명 원문보기 기사목차
닫기